| 3.47 -0.04 (-1.14%) | 07-27 15:17 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.49  |
1-year : | 4.78 |
| Resists | First : | 3.84 |
Second : | 4.09 |
| Pivot price | 3.65 |
|||
| Supports | First : | 3.44 |
Second : | 2.86 |
| MAs | MA(5) : | 3.55 |
MA(20) : | 3.72 |
| MA(100) : | 3.76 |
MA(250) : | 3.39  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 15.2 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 5.15 | Low : | 1.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SABS ] has closed above bottom band by 16.0%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.62 - 3.64 | 3.64 - 3.66 |
| Low: | 3.42 - 3.45 | 3.45 - 3.46 |
| Close: | 3.48 - 3.51 | 3.51 - 3.54 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Mon, 27 Jul 2026
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mon, 27 Jul 2026
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
Mon, 27 Jul 2026
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey
Wed, 15 Jul 2026
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance
Tue, 30 Jun 2026
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance
Fri, 26 Jun 2026
SABS Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 92.4 (%) |
| Shares Short | 4,380 (K) |
| Shares Short P.Month | 2,880 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -0.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.52 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -5.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|